CHESTERFIELD, United Kingdom, Dec. 15, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, will present on Monday, Jan. 11, 2016, at the J.P. Morgan 34th Annual Healthcare Conference at The Westin St. Francis on Union Square, 335 Powell St., in San Francisco. The conference is Jan. 11-14, 2016.
Mark Trudeau, President and Chief Executive Officer; Matt Harbaugh, Senior Vice President and Chief Financial Officer; and Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, will represent the company in a presentation scheduled to begin at 9 a.m. Pacific Time, with a question-and-answer session to follow from 9:30 a.m. to 9:55 a.m.
Individuals who cannot attend the meeting in person can find webcast information at: http://www.mallinckrodt.com/investors. A replay will also be available following the meeting.
Mallinckrodt is a global specialty biopharmaceutical and imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Senior Communications Manager
Senior Vice President, Communications and Public Affairs
SOURCE Mallinckrodt plc